{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T18:49:35Z","timestamp":1776019775641,"version":"3.50.1"},"reference-count":29,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2006,9,13]],"date-time":"2006-09-13T00:00:00Z","timestamp":1158105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2007,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Previous clinical and pre\u2010clinical research has demonstrated synergy between anti\u2010angiogenic agents and cytotoxic chemotherapy. This trial was undertaken to investigate whether the combination of cyclophosphamide and thalidomide would be active against pediatric tumors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedure<\/jats:title><jats:p>Patients with pediatric malignancies who had no remaining conventional therapeutic options were recruited from January 1999 to May 2001. They received thalidomide (6\u201312 mg\/kg po every day; maximum daily dose 800 mg) and cyclophosphamide (1,200 mg\/m<jats:sup>2<\/jats:sup> IV every 28 days).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty\u2010seven patients were enrolled on the study. Seventeen were male and 10 were female. Median age at the time of registration was 15 years (range 1\u201354 years). The median number of prior treatment regimens was four. Twenty\u2010one patients were evaluable for response; 1 had a partial response (Hodgkin disease), 1 demonstrated stable disease (neuroendocrine tumor), and 19 had progressive disease. The most common toxicities were hematological (leukocytopenia and neutropenia) and gastrointestinal. One patient experienced a grade 3 rash. Fatigue and daytime somnolence were variable. No peripheral neuropathy was observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The combination of thalidomide and cyclophosphamide as described herein has a modest and tolerable toxicity profile but little evidence of efficacy. Pediatr Blood Cancer 2007;49:261\u2013265. \u00a9 2006 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.21045","type":"journal-article","created":{"date-parts":[[2006,9,13]],"date-time":"2006-09-13T19:53:37Z","timestamp":1158177217000},"page":"261-265","source":"Crossref","is-referenced-by-count":14,"title":["A phase II trial of thalidomide and cyclophosphamide in patients with recurrent or refractory pediatric malignancies"],"prefix":"10.1002","volume":"49","author":[{"given":"Stephen W.","family":"Gilheeney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Lyden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirley","family":"Sgouros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuno","family":"Antunes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Gerald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Lis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard T.","family":"Thaler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya","family":"Trippett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard","family":"Wexler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ira J.","family":"Dunkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,9,13]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/82.1.4"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1101-1194"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0202-128"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16308-3"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.9.4082"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.177.6.1675"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.173.3.699"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M100938200"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A098"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1359-4117.2002.01011.x"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012554328801"},{"key":"e_1_2_5_13_2","first-page":"937","article-title":"Thalidomide in the management of chronic graft\u2010versus\u2010host disease in children folowing bone marrow transplantation","volume":"14","author":"Cole C","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0902-4441.2003.00188.x"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1025485031112"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008390-200412000-00014"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005718628223"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.045"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.02.061"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:NEON.0000021803.01170.03"},{"key":"e_1_2_5_21_2","first-page":"86","article-title":"Paradoxical effect of thalidomide prophylaxis on chronic graft\u2010versus\u2010host disease","volume":"2","author":"Chao N","year":"1996","journal-title":"Biol Blood Marrow Transplant"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-004-0816-z"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.04.565"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.04.006"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1369"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresrev.2004.03.001"},{"key":"e_1_2_5_27_2","first-page":"1759","article-title":"Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy","volume":"24","author":"Drevs J","year":"2004","journal-title":"Anticancer Res"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-0580"},{"key":"e_1_2_5_29_2","first-page":"4342","article-title":"Maximum tolerable dose and low\u2010dose metronomic chemotherapy have opposite effects on the mobilization of viability of circulating endothelial progenitor cells","volume":"63","author":"Bertolini F","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mph.0000183863.10792.d4"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.21045","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.21045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T01:02:01Z","timestamp":1697677321000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.21045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,13]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["10.1002\/pbc.21045"],"URL":"https:\/\/doi.org\/10.1002\/pbc.21045","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9,13]]}}}